OncoMatch/Clinical Trials/NCT06782412
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Is NCT06782412 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for oesophageal cancer.
The aim of the project is to demonstrate superior detection ratio of \[18F\]AlF-FAPI-74 PET/CT compared to \[18F\]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of \[18F\]AlF-FAPI-74 PET/CT in oncological patients with a clinically challenging situation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Pancreatic Cancer
Disease stage
Required: Stage CT1-4N0-3M0, CT1-4N0-2M0-1 (EXCEPT UPFRONT RESECTABLE PATIENTS) (TNM)
Excluded: Stage UPFRONT RESECTABLE PATIENTS (PDAC COHORT)
TNM classification: cT1-4N0-3M0 (OGA); cT1-4N0-2M0-1, with the exception of upfront resectable patients (PDAC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify